The global Ophthalmic Anti-infective Drug market size is predicted to grow from US$ 1581 million in 2025 to US$ 1934 million in 2031; it is expected to grow at a CAGR of 3.4% from 2025 to 2031.
Ophthalmic anti-infectives are anti-infectives contained in a product formulated especially to be instilled or applied in the eye or eyes. Ophthalmic anti-infectives include eyedrops, gels or ointments. Anti-infectives are drugs that can either kill an infectious agent or inhibit it from spreading. Anti-infectives include antibiotics and antibacterials, antifungals, antivirals and antiprotozoals.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淥phthalmic Anti-infective Drug Industry Forecast鈥� looks at past sales and reviews total world Ophthalmic Anti-infective Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Ophthalmic Anti-infective Drug sales for 2025 through 2031. With Ophthalmic Anti-infective Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ophthalmic Anti-infective Drug industry.
This Insight Report provides a comprehensive analysis of the global Ophthalmic Anti-infective Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Ophthalmic Anti-infective Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Ophthalmic Anti-infective Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ophthalmic Anti-infective Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ophthalmic Anti-infective Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Ophthalmic Anti-infective Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
Eyedrops
Gels
Ointments
Other
Segmentation by Application:
Hospital
Retail Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alcon
AbbVie
Bausch Health
Santen Pharmaceutical
Lupin Pharmaceuticals
Apotex
Akorn
Johnson & Johnson
Thea pharmaceuticals
URSAPHARM
SIMILASAN
Jianfeng Group
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Ophthalmic Anti-infective Drug 麻豆原创 Size (2020-2031)
2.1.2 Ophthalmic Anti-infective Drug 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Ophthalmic Anti-infective Drug by Country/Region (2020, 2024 & 2031)
2.2 Ophthalmic Anti-infective Drug Segment by Type
2.2.1 Eyedrops
2.2.2 Gels
2.2.3 Ointments
2.2.4 Other
2.3 Ophthalmic Anti-infective Drug 麻豆原创 Size by Type
2.3.1 Ophthalmic Anti-infective Drug 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Ophthalmic Anti-infective Drug 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Ophthalmic Anti-infective Drug Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Others
2.5 Ophthalmic Anti-infective Drug 麻豆原创 Size by Application
2.5.1 Ophthalmic Anti-infective Drug 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Ophthalmic Anti-infective Drug 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Ophthalmic Anti-infective Drug 麻豆原创 Size by Player
3.1 Ophthalmic Anti-infective Drug 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Ophthalmic Anti-infective Drug Revenue by Player (2020-2025)
3.1.2 Global Ophthalmic Anti-infective Drug Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Ophthalmic Anti-infective Drug Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Ophthalmic Anti-infective Drug by Region
4.1 Ophthalmic Anti-infective Drug 麻豆原创 Size by Region (2020-2025)
4.2 Global Ophthalmic Anti-infective Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Ophthalmic Anti-infective Drug 麻豆原创 Size Growth (2020-2025)
4.4 APAC Ophthalmic Anti-infective Drug 麻豆原创 Size Growth (2020-2025)
4.5 Europe Ophthalmic Anti-infective Drug 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Ophthalmic Anti-infective Drug 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Ophthalmic Anti-infective Drug 麻豆原创 Size by Country (2020-2025)
5.2 Americas Ophthalmic Anti-infective Drug 麻豆原创 Size by Type (2020-2025)
5.3 Americas Ophthalmic Anti-infective Drug 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ophthalmic Anti-infective Drug 麻豆原创 Size by Region (2020-2025)
6.2 APAC Ophthalmic Anti-infective Drug 麻豆原创 Size by Type (2020-2025)
6.3 APAC Ophthalmic Anti-infective Drug 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Ophthalmic Anti-infective Drug 麻豆原创 Size by Country (2020-2025)
7.2 Europe Ophthalmic Anti-infective Drug 麻豆原创 Size by Type (2020-2025)
7.3 Europe Ophthalmic Anti-infective Drug 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ophthalmic Anti-infective Drug by Region (2020-2025)
8.2 Middle East & Africa Ophthalmic Anti-infective Drug 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Ophthalmic Anti-infective Drug 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Ophthalmic Anti-infective Drug 麻豆原创 Forecast
10.1 Global Ophthalmic Anti-infective Drug Forecast by Region (2026-2031)
10.1.1 Global Ophthalmic Anti-infective Drug Forecast by Region (2026-2031)
10.1.2 Americas Ophthalmic Anti-infective Drug Forecast
10.1.3 APAC Ophthalmic Anti-infective Drug Forecast
10.1.4 Europe Ophthalmic Anti-infective Drug Forecast
10.1.5 Middle East & Africa Ophthalmic Anti-infective Drug Forecast
10.2 Americas Ophthalmic Anti-infective Drug Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.2.2 Canada 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.2.3 Mexico 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.2.4 Brazil 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.3 APAC Ophthalmic Anti-infective Drug Forecast by Region (2026-2031)
10.3.1 China Ophthalmic Anti-infective Drug 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.3.3 Korea 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.3.4 Southeast Asia 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.3.5 India 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.3.6 Australia 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.4 Europe Ophthalmic Anti-infective Drug Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.4.2 France 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.4.3 UK 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.4.4 Italy 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.4.5 Russia 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.5 Middle East & Africa Ophthalmic Anti-infective Drug Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.5.2 South Africa 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.5.3 Israel 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.5.4 Turkey 麻豆原创 Ophthalmic Anti-infective Drug Forecast
10.6 Global Ophthalmic Anti-infective Drug Forecast by Type (2026-2031)
10.7 Global Ophthalmic Anti-infective Drug Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Ophthalmic Anti-infective Drug Forecast
11 Key Players Analysis
11.1 Alcon
11.1.1 Alcon Company Information
11.1.2 Alcon Ophthalmic Anti-infective Drug Product Offered
11.1.3 Alcon Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Alcon Main Business Overview
11.1.5 Alcon Latest Developments
11.2 AbbVie
11.2.1 AbbVie Company Information
11.2.2 AbbVie Ophthalmic Anti-infective Drug Product Offered
11.2.3 AbbVie Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 AbbVie Main Business Overview
11.2.5 AbbVie Latest Developments
11.3 Bausch Health
11.3.1 Bausch Health Company Information
11.3.2 Bausch Health Ophthalmic Anti-infective Drug Product Offered
11.3.3 Bausch Health Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Bausch Health Main Business Overview
11.3.5 Bausch Health Latest Developments
11.4 Santen Pharmaceutical
11.4.1 Santen Pharmaceutical Company Information
11.4.2 Santen Pharmaceutical Ophthalmic Anti-infective Drug Product Offered
11.4.3 Santen Pharmaceutical Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Santen Pharmaceutical Main Business Overview
11.4.5 Santen Pharmaceutical Latest Developments
11.5 Lupin Pharmaceuticals
11.5.1 Lupin Pharmaceuticals Company Information
11.5.2 Lupin Pharmaceuticals Ophthalmic Anti-infective Drug Product Offered
11.5.3 Lupin Pharmaceuticals Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Lupin Pharmaceuticals Main Business Overview
11.5.5 Lupin Pharmaceuticals Latest Developments
11.6 Apotex
11.6.1 Apotex Company Information
11.6.2 Apotex Ophthalmic Anti-infective Drug Product Offered
11.6.3 Apotex Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Apotex Main Business Overview
11.6.5 Apotex Latest Developments
11.7 Akorn
11.7.1 Akorn Company Information
11.7.2 Akorn Ophthalmic Anti-infective Drug Product Offered
11.7.3 Akorn Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Akorn Main Business Overview
11.7.5 Akorn Latest Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Information
11.8.2 Johnson & Johnson Ophthalmic Anti-infective Drug Product Offered
11.8.3 Johnson & Johnson Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Johnson & Johnson Main Business Overview
11.8.5 Johnson & Johnson Latest Developments
11.9 Thea pharmaceuticals
11.9.1 Thea pharmaceuticals Company Information
11.9.2 Thea pharmaceuticals Ophthalmic Anti-infective Drug Product Offered
11.9.3 Thea pharmaceuticals Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Thea pharmaceuticals Main Business Overview
11.9.5 Thea pharmaceuticals Latest Developments
11.10 URSAPHARM
11.10.1 URSAPHARM Company Information
11.10.2 URSAPHARM Ophthalmic Anti-infective Drug Product Offered
11.10.3 URSAPHARM Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 URSAPHARM Main Business Overview
11.10.5 URSAPHARM Latest Developments
11.11 SIMILASAN
11.11.1 SIMILASAN Company Information
11.11.2 SIMILASAN Ophthalmic Anti-infective Drug Product Offered
11.11.3 SIMILASAN Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 SIMILASAN Main Business Overview
11.11.5 SIMILASAN Latest Developments
11.12 Jianfeng Group
11.12.1 Jianfeng Group Company Information
11.12.2 Jianfeng Group Ophthalmic Anti-infective Drug Product Offered
11.12.3 Jianfeng Group Ophthalmic Anti-infective Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Jianfeng Group Main Business Overview
11.12.5 Jianfeng Group Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
